METASTATIC RENAL CELL CARCINOMA

This study is testing a drug called adavosertib in people with advanced solid tumors that have spread and have a specific genetic change called SETD2-deficiency. The goal is to see if the drug can shrink or stop the growth of these tumors by blocking enzymes the cancer cells need…

This study is testing if precisely targeted radiation can control kidney cancer that has spread to only a few other body sites. The goal is to see if this approach can delay or avoid the need for stronger, body-wide drug treatments. It involves 123 adults with a limited number of…

This study is testing whether combining two drugs, evolocumab and nivolumab, can help control advanced kidney cancer that has stopped responding to standard immunotherapy or other targeted drugs. It will involve about 10 adults with metastatic kidney cancer to see if the combinat…

This early-stage study is testing if adding a probiotic called CBM588 to standard cancer drugs (cabozantinib and nivolumab) can help patients with advanced kidney cancer. The probiotic aims to improve the mix of 'good' bacteria in the gut, which might help the body's immune syste…

This early-stage study aimed to test the safety and early effectiveness of a personalized cell therapy called STIL101. The therapy involved growing a patient's own cancer-fighting immune cells (T-cells) from a tumor sample in a lab and then infusing them back. It was designed for…

This study is testing whether adding a new drug called ixazomib to two standard chemotherapy drugs works better for controlling an aggressive type of kidney cancer that has spread. It is for patients aged 12 and older whose cancer has progressed after other treatments and who hav…

This study compares two existing drugs, cabozantinib and sunitinib, to see which is safer and more effective at controlling advanced kidney cancer that has spread. It is for patients with specific, less common types of kidney cancer. Participants are randomly assigned to take one…

This early-stage trial is testing whether injecting a nanoparticle called NBTXR3 directly into a tumor, then activating it with radiation, can make immunotherapy work better for people with advanced cancers. The study will enroll about 145 patients with various cancers that have …

This early-phase study is testing whether combining two cancer drugs (cabozantinib and nivolumab) with targeted radiation is safe for people whose kidney cancer has spread to the brain. The main goal is to see if patients can tolerate this three-part treatment without severe side…

This large study is testing if adding an immunotherapy drug called nivolumab to standard kidney cancer surgery helps prevent the cancer from coming back. About 819 patients with kidney cancer that hasn't spread far will have surgery, with half also receiving the drug before and a…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This study aimed to see if time-restricted eating (limiting food to a 10-hour daily window) could improve outcomes for people with advanced head & neck or kidney cancer receiving immunotherapy. Researchers wanted to learn if this eating pattern changes gut bacteria and the body's…

This early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs …

This study is testing whether keeping blood pressure very low (under 120) is better than the usual target (under 140) for patients with advanced kidney or thyroid cancer who are starting specific cancer drugs. The goal is to see if this intensive approach is doable, safe, and hel…

This study is testing a new combination treatment for people with advanced lung cancer, melanoma, kidney cancer, or head and neck cancer that has stopped responding to standard immunotherapy. The treatment involves three parts: a targeted radiation dose to one tumor, injections o…

This study is testing whether combining two cancer drugs works better than using just one to treat an aggressive form of kidney cancer that has spread or cannot be removed by surgery. The trial is enrolling patients of all ages, from children to adults. Researchers want to see if…

This large, late-stage trial is testing if adding a precise, high-dose radiation treatment to the standard drug therapy helps people with kidney cancer that has spread to a limited number of other body sites. It will compare survival, side effects, and quality of life between pat…

This study is testing whether a mindfulness app is a practical tool to help people with advanced kidney cancer that has spread. It aims to see if using the app for 20-30 minutes a day, at least 4 days a week for 4 weeks, can help reduce anxiety, fear of the cancer returning, and …

This early-stage study is testing a tiny, implantable device to see if it can safely help doctors figure out which cancer drugs work best for an individual's kidney tumor. The device, placed into a tumor before surgery, releases tiny amounts of 19 different drugs already used to …

This study aims to understand how different treatments for advanced kidney cancer affect patients' quality of life and symptoms in everyday practice. It will follow about 470 patients already receiving standard care, collecting information through questionnaires and medical recor…

This study is observing how patients with advanced kidney cancer respond to treatment with the drug cabozantinib, either alone or combined with nivolumab, in everyday clinical practice. It involves 224 adults who are already receiving this as their first treatment. The main goal …